BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 17128418)

  • 1. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT; Levis M; Small D
    Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
    Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
    Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.
    Hunter HM; Pallis M; Seedhouse CH; Grundy M; Gray C; Russell NH
    Br J Haematol; 2004 Oct; 127(1):26-33. PubMed ID: 15384974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
    Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.
    Scholl S; Müller R; Clement JH; Loncarevic IF; Böhmer FD; Höffken K
    Leuk Res; 2006 May; 30(5):633-42. PubMed ID: 16473406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
    Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
    Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
    Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
    Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
    Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3/ ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signalling.
    Katsumi A; Kiyoi H; Abe A; Tanizaki R; Iwasaki T; Kobayashi M; Matsushita T; Kaibuchi K; Senga T; Kojima T; Kohno T; Hamaguchi M; Naoe T
    Eur J Haematol; 2011 Mar; 86(3):191-8. PubMed ID: 21114537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival.
    Masson K; Liu T; Khan R; Sun J; Rönnstrand L
    Br J Haematol; 2009 Jul; 146(2):193-202. PubMed ID: 19438505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
    Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.
    Muranyi AL; Dedhar S; Hogge DE
    Exp Hematol; 2009 Apr; 37(4):450-60. PubMed ID: 19302919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.
    Masson K; Rönnstrand L
    Cell Signal; 2009 Dec; 21(12):1717-26. PubMed ID: 19540337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).
    Ozawa Y; Williams AH; Estes ML; Matsushita N; Boschelli F; Jove R; List AF
    Leuk Res; 2008 Jun; 32(6):893-903. PubMed ID: 18179820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
    Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.